Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$139.01 USD

139.01
947,434

+0.87 (0.63%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $139.04 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Philips (PHG) Agrees to a Consent Decree With DOJ and FDA

by Zacks Equity Research

Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.

GE HealthCare (GEHC) to Showcase Enhanced Breast Cancer Imaging

by Zacks Equity Research

GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

by Zacks Equity Research

DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

DaVita HealthCare (DVA) Stock Moves -0.75%: What You Should Know

by Zacks Equity Research

In the most recent trading session, DaVita HealthCare (DVA) closed at $130.42, indicating a -0.75% shift from the previous trading day.

QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing

by Zacks Equity Research

QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

by Zacks Equity Research

Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.

Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

by Zacks Equity Research

Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod

by Zacks Equity Research

Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).

Ethan Feller headshot

Market Jitters: 2 Top Ranked Stocks for Defensive Positioning

by Ethan Feller

With the jump in inflation and rise in interest rate uncertainty investors may want to consider defensive stocks

Here's Why You Should Add DaVita (DVA) to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Reasons to Hold Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Cresco Labs Inc. (CRLBF) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cresco Labs Inc. (CRLBF) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Is Most-Watched Stock DaVita Inc. (DVA) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching DaVita HealthCare (DVA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia

by Zacks Equity Research

Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.

Why You Should Retain Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.

Why You Should Retain Inari Medical (NARI) Stock for Now

by Zacks Equity Research

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.